Chronomics' CEO and founder Dr Tom Stubbs
Chronomics, a pioneering company in health-tech innovation, has just launched a consumer epigenetic testing kit. Chronomics has successfully secured more than £1.12 million in funding, including significant investment from venture capital firm Anthemis, and follow on funding from early-stage biotech investors, SOSV.
Chronomics seeks to revolutionise attitudes towards health management, from a generalist and reactive approach, to one that is personalised and proactive. Through a unique epigenetic saliva test, Chronomics profiles specific lifestyle and environmental indicators to provide accurate insights into a person’s health – such as their biological age, metabolic status, and the impact of smoke exposure on the body.
Chronomics has secured investment from two world-leading venture capital firms. SOSV initially invested in Chronomics through the RebelBio programme and has since provided follow on investment. Anthemis, a venture investment and advisory firm dedicated to cultivating change in financial services, has also provided Chronomics with significant investment.
Chronomics also secured funding from leading angel investors, including Laurence Garrett, senior partner with Highland Europe. Garrett was previously on the board of BlueGnome Ltd., a pioneer in gene testing to improve IVF success rate. Laurence has significant experience as a private investor in AI and deep tech companies, such as Speechmatics and FeatureSpace.
The company’s success in securing competitive funding will enable Chronomics to continue to harness the increased demand for personalised health management, as they continue to forge a company that is pioneering in its field.
“Physical health and mental wellbeing are crucial pieces to the puzzle of an individual's financial wellness.” said Anthemis’ Vica Manos. She added: “The team is combining a brand-new data source and cutting-edge science to help consumers make better, more informed decisions about their lifestyle, which is really exciting. We are delighted to support the Chronomics team as they gear up for the next phase of their journey.”
Bill Liao, venture partner with SOSV said “We have always been interested in the DNA testing space, and Chronomics is the first company that we have discovered that radically departs from the ‘once in a lifetime’ test business model, to a subscription. It actually shows how your epigenome changes over time, why that matters and what to do about it! What's more, it's in an area completely untapped in terms of consumer access.”
Laurence Garrett said “The Chronomics team are academically exceptional. The company has responded to an increased desire amongst people to improve the quality of their lives through sound scientific data about their epigenetic profile. I am grateful to Tom and the team to allow me to become an investor in their business.”
CEO and founder Dr Tom Stubbs said, “Reaching £1.12 million in seed funding is a momentous milestone for Chronomics, having just launched the company last year. Receiving the support of prominent backers reflects their confidence in our company, and our vision of a future of personalised and proactive health management.”
Our BQ Bulletin emails will land in your inbox at 7.30am, Monday to Friday, with a mix of the latest local business news, national news, and features to inspire you. Sign up here!
Click here to read our privacy statement